Hepatitis C virus (HCV) often causes persistent infection and is an increasingly important factor in the etiology of fibrosis/cirrhosis and hepatocellular carcinoma, although the mechanisms for the disease processes remain unclear. We have shown previously that HCV infection generates an epithelial-mesenchymal transition state and tumor-initiating cancer stem-like cells in human hepatocytes. In this study, we investigated whether HCV-induced tumor-initiating cancer stemlike cells when implanted into mice activate stromal fibroblasts. A number of fibroblast activation markers, including matrix metalloproteinase 2, were significantly increased at the mRNA or protein level in the xenograft tumors, suggesting the presence of tumor-associated fibroblasts. Fibroblast activation markers of murine origin were specifically increased in tumor, suggesting that fibroblasts migrate to form stroma. Next, we demonstrated that conditioned medium from HCVinfected human hepatocytes activates fibrosis-related markers in hepatic stellate cells. We further observed that these HCV-infected hepatocytes express transforming growth factor beta, which activates stromal fibroblast markers. Subsequent analysis suggested that anti-transforming growth factor beta neutralizing antibody, when incubated with conditioned medium from HCV-infected hepatocytes, inhibits fibrosis marker activation in primary human hepatic stellate cells. Conclusion: HCV-infected hepatocytes induce local fibroblast activation by secretion of transforming growth factor beta, and a preneoplastic or tumor state of the hepatocytes influences the network for the tumor-associated fibroblast environment. (HEPATOLOGY 2017;66:1766-1778 
H epatitis C virus (HCV) often causes persistent infection and is an important factor in the etiology of fibrosis/cirrhosis and hepatocellular carcinoma (HCC). (1) (2) (3) Although HCV primarily infects and replicates in hepatocytes, it impairs normal functions of other liver cells and promotes fibrosis/cirrhosis. Direct-acting antiviral agents may significantly improve the outcome from HCV infection if detected early after infection, but treatment is costly and already faces issues such as viral mutation, relapse, and reinfection following therapy. Some patients still progress to liver failure and/or carcinoma despite being cured of HCV infection after therapy. (4) (5) (6) HCV-associated HCC is normally seen in the presence of fibrosis/cirrhosis, although the mechanism of this association is unclear at present. The HCV genome does not integrate into its host genome and has a predominantly cytoplasmic life cycle. Therefore, liver fibrosis/cirrhosis and HCC appear to involve mechanisms induced from HCV replication. We have shown that HCV infection of primary human hepatocytes promotes epithelial-mesenchymal transition (EMT)-related gene expression and generates tumorinitiating cancer stem-like cells (TISCs). (7, 8) Desmoplasia is the growth of fibrous or connective tissue that usually occurs around a malignant neoplasm, causing dense fibrosis around the tumor. Myofibroblasts are increasingly recognized as a cell type within the tumor microenvironment that impacts tumor growth. These cells are integral for fibronectin fibril assembly and contribute importantly to matrix stiffness and tumor desmoplasia. (9) The tumor microenvironment, including stromal myofibroblasts and associated matrix proteins, regulates cancer cell proliferation and invasion. (10) Quiescent stellate cells undergo activation to adopt a fibroblast morphology and secrete type 1 collagen, the principal matrix protein responsible for the development of liver fibrosis and cancer progression. (11, 12) Activated hepatic stellate cells (HSCs) are also a rich source of growth factors and cytokines that promote tumor progression and angiogenesis. (13) Additionally, they regulate extracellular matrix turnover and suppress the antitumor immune response, creating a prometastatic microenvironment for tumor cells. Antifibrotic effects may therefore result either from a direct effect on fibrogenic cells or from nonspecific anti-inflammatory effects.
Quiescent stellate cell activation may occur from transforming growth factor beta (TGF-b) secreted by EMT/preneoplastic hepatocytes. TGF-bs are multifunctional cytokines and regulate a broad range of biological processes, including cell proliferation, survival, and differentiation. (14, 15) The three isoforms, TGFb1, TGF-b2, and TGF-b3, have sequence homology and bind to the same receptors, although their in vivo functions reveal striking differences, with unique biological importance and functional nonredundancy. Both TGF-b1 and TGF-b2 play a role in immune tolerance and induce fibrosis, while TGF-b3 counteracts tissue fibrosis. TGF-b from polarized M2 macrophages also plays a role in fibrotic processes. (16, 17) In this study, we examined how HCV infection activates HSCs to promote desmoplasia. Implantation of HCV-associated TISCs was examined for enhancement of tumor-associated fibroblasts (TAFs) in a xenograft model. Our results demonstrated that HCVinfected human heaptocytes secreting TGF-b induced a cellular microenvironment that promotes induction of fibroblast activation for stromal changes.
Materials and Methods

CELL CULTURE
Immortalized human hepatocytes were generated by transfection of a plasmid DNA expressing HCV core genomic region of genotype 1a (Genbank accession number M62321) into primary human hepatocytes under the control of a cytomegalovirus promoter. (18) Cells of human hepatocyte origin (Huh7.5 and Huh7.5 cells harboring the HCV genotype 2a genome-length replicon with the Renilla luciferase reporter gene, Rep2a-Rluc cells; kindly provided by Hengli Tang, Florida State University), human embryonic kidney 293 (HEK293) cells, and human foreskin fibroblasts (HFFs) were used. Cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and penicillin-streptomycin at 378C in a 5% CO 2 atmosphere. Immortalized human HSCs, LX2 cells (19) (kindly provided by Scott Friedman, Mount Sinai School of Medicine, New York, NY), were maintained in Dulbecco's modified Eagle medium supplemented with 2% fetal bovine serum and penicillin-streptomycin at 378C in a 5% CO 2 atmosphere. Primary human HSCs were procured (ScienCell, Carlsbad, CA) and grown on poly-L-lysine-coated flasks in Dulbecco's modified Eagle medium, supplemented with 2% fetal bovine serum and 2 3 L-glutamine at 378C in a 5% CO 2 with cell culture-grown HCV genotype 2a (clone JFH1) at a multiplicity of infection of 0.2 and examined for phenotypic and molecular changes.
XENOGRAFT MOUSE MODEL
TISCs generated from HCV-infected late-passage immortalized human hepatocytes were implanted into flanks of NSG mice (n 5 4) for tumor growth, as described. (7) Mice were sacrificed when tumor volume reached 1.2 cm 3 , and fibrosis markers were analyzed in xenografted tumors by quantitative real-time PCR or western blot analysis.
TREATMENT OF HSCs
HSCs were treated with conditioned medium (CM) from HCV-infected hepatocytes, TGF-b1 (2.5, 5, or 10 ng/mL; R&D Systems, Minneapolis, MN), or TGF-b2 (5, 10, or 20 ng/mL; R&D Systems). Whenever necessary, HSCs were treated with CM neutralized by antibody to TGF-b1 (2 mg/mL; Abcam, Cambridge, MA) or TGF-b2 (2 mg/mL; R&D Systems) or negative control antibody for 24 hours, and RNA was isolated for subsequent analysis.
WESTERN BLOT ANALYSIS
Proteins in cell lysates were separated and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories). The blot was blocked with 5% skim milk and incubated with a specific primary antibody as a probe, followed by treatment with a secondary antibody conjugated to horseradish peroxidase (Bio-Rad Laboratories). The membrane was probed with antibodies to vimentin (Cell Signaling), fibroblast-specific protein 1 (FSP-1; EMD Millipore), alpha-smooth muscle actin (a-SMA), matrix metalloproteinase 2 (MMP2; Santa Cruz), TGF-b1 (Abcam), and TGF-b2 (R&D Systems). The membrane was reprobed with actin or glyceraldehyde 3-phosphate dehydrogenase as an internal control. The protein band was detected with SuperSignal West Pico ECL reagents (Pierce). Densitometric scanning of western blots was performed by ImageJ software (National Institutes of Health).
QUALITATIVE REAL-TIME PCR
Total RNA was isolated using a Trizol reagent (Qiagen, CA). RNA was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). Complementary DNA was synthesized using random hexamers and a Superscript III reverse transcriptase kit (Invitrogen, CA). Quantitative real-time PCR was performed with complementary DNA using TaqMan gene expression PCR master mix and 6-carboxyfluorescein-MGB primers for mouse ACTA2 (assay Mm00725412_s1); collagen type 1, alpha 2 (COL1A2; assay Mm00483888_m1); COL1A1 (assay Mm00801666_g1); connective tissue growth factor (CTGF; assay Mm01192933_g1); vimentin (assay Mm01333430_m1); FSP-1 (assay Mm00803372_g1); and 18S RNA (assay Mm04277571_s1). 6-Carboxyfluorescein-MGB primers for human ACTA2 (assay Hs00426835_g1), TGFb1 (assay Hs00998133_m1), TGFb2 (assay Hs00234244_m1), TGFb3 (assay Hs01086000_m1), COL1A1 (assay Hs00164004_m1), MMP2 (assay Hs01548727_m1), CTGF (assay Hs01026927_g1), and 18S ribosomal RNA (assay Hs03928985_g1) as an endogenous control were used. The relative gene expression levels were normalized to the 18S ribosomal RNA level using the 2-DDCT formula (DDCT 5 DCT sample 2 DCT untreated control). Commercially available control liver RNAs (C1 and C2) (Clonetics, CA; CloneTech, CA) were procured and used in this study for comparison.
STATISTICAL ANALYSIS
The results are presented as means 6 standard deviations. Data were analyzed by the Student t test with a two-tailed distribution. P < 0.05 was considered statistically significant.
Results
XENOGRAFT TUMORS FROM HCV-INDUCED TISCs RECRUIT AND ACTIVATE MURINE FIBROBLASTS
HCV infection in human liver induces fibrosis/ cirrhosis and is related to an annual risk of approximately 1% for HCC. (20) We generated xenograft multinodular tumors by implanting TISCs into NSG mice and dissected the tumors for biochemical analysis. To examine TAF marker expression, RNA was isolated from portions of the representative tumors (T1 and T2). HCV-induced TISCs (C) and commercially available control liver (C1 and C2) RNAs were used for comparison. Expression of a-SMA, COL1A2, COL1A1, vimentin, CTGF, and FSP-1 mRNAs was analyzed by quantitative real-time PCR (Fig. 1A) . RNAs from C, C1, or C2 did not exhibit the presence of TAF markers compared to RNA from xenograft tumors (T1 or T2). We observed a significantly higher expression level of mRNAs in tumors for collagen and a type 3 intermediate filament protein vimentin   FIG. 1 . Analyses for TAF activation markers in xenograft tumors after implantation of TISCs into NSG mice. RNA from xenograft tumors (T1 and T2) was isolated and analyzed for expression of a-SMA, COL1A2, COL1A1, vimentin, CTGF, and FSP-1 by quantitative real-time PCR and normalized with 18S RNA (A). TISCs grown on a Petri dish (C) and control human liver (C1 and C2) RNAs were used for comparison. Species-specific analysis of TAF activation markers in xenograft tumors (B). RNA from T1 or T2 tumors was analyzed for expression of a-SMA and COL1A2 using mouse-specific and human-specific primers. Statistical significance of the results was analyzed using the two-tailed Student t test: *P < 0.05, **P < 0.01.
FIG. 2.
Collagen fiber staining and TAF-related protein expression status in xenograft tumor. Staining with sirius red/fast green of representative tumor section exhibiting collagen fibers is indicated by arrows (A). Hematoxylin and eosin staining of cells used for implantation and tumor generation is shown separately (B). Tumor lysates were analyzed for expression of vimentin, a-SMA, and FSP-1 by western blot using specific antibodies (C). TISCs (C) or smooth muscle lysates were used as control for comparison. Glyceraldehyde 3-phosphate dehydrogenase was used as a housekeeping protein. Densitometric scanning of western blot results is shown (D-F). Value from C was arbitrarily chosen as 1. Values represent mean from three independent experiments 6 standard deviation. Statistical significance was analyzed using the two-tailed Student t test: *P < 0.05, **P < 0.01. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase. (>1,000-fold), a matricellular protein CTGF (>400-fold), and a-SMA and FSP-1 (>20-fold). Next, we verified whether activation of these fibroblast markers is from recruitment of mouse fibroblasts to implanted human hepatocytes. For this, we examined for amplification of a-SMA and COL1A2 in xenograft tissue using mouse-specific or human-specific primers by quantitative real-time PCR. Interestingly, expression of the a-SMA or COL1A2 gene was specifically recognized by mouse-specific primers, whereas humanspecific primers did not show any significant amplification (Fig. 1B) . Thus, our results suggest that murine fibroblasts were recruited and activated by xenograft tumors.
XENOGRAFT TUMORS ENHANCE CANCER-ASSOCIATED FIBRO-BLAST-RELATED PROTEINS
We examined formalin-fixed xenograft tumor sections for architectural changes. Tumor sections were stained with sirius red for collagen and separately stained with hematoxylin and eosin. Sirius red staining exhibited collagen fibers ( Fig. 2A) , while hematoxylin and eosin-stained cells appeared as blue in a violet background composed of hepatocytes with nucleus and cytoplasm (Fig. 2B) . TAF marker proteins in xenograft tumors were separately examined from tumor lysates by western blot analysis. TISCs (C) and mouse smooth muscle were used as controls. An increase in total vimentin, a-SMA, and FSP-1 protein levels was observed (Fig. 2C) . The a-SMA protein was undetectable from TISCs (C), as expected. Glyceraldehyde 3-phosphate dehydrogenase was used as a housekeeping protein for normalization. Densitometric scanning results for expression differences of these marker proteins are also shown (Fig. 2D-F) . Our results clearly suggested an up-regulation of fibroblast markers at the protein level in xenograft tumors.
TGF-b IS SIGNIFICANTLY UP-REGULATED IN HCV-INFETED HEPATOCYTES
Primary human hepatocytes displaying EMT after HCV infection modulate cytokine, transcription factor, and metalloproteinase mRNA synthesis. (8) Our transcriptome analysis results indicated that a number of important molecules, including TGF-b and MMP2, were elevated in HCV-infected hepatocytes. TGF-b is a multifunctional cytokine and plays an important role in a broad range of biological processes, including cell proliferation, survival, and differentiation. To further verify array data, Huh7.5 cells were infected with HCV genotype 2a (clone JFH1) and analyzed for expression of TGF-b isoforms by quantitative real-time PCR using specific primers. TGF-b1 and TGF-b2 mRNA was increased compared to FIG. 4 . TGF-b1 is up-regulated in chronically HCV-infected human liver biopsy specimens. Expression of TGF-b1 and TGF-b2 isoforms was analyzed by quantitative real-time PCR for comparison in chronically HCV-infected human liver biopsy specimens. Control human liver RNA from two donors was pooled and included for comparison. Values represent mean from three independent experiments 6 standard deviation. Statistical significance was analyzed using the two-tailed Student t test: *P < 0.05, **P < 0.01. Error bar without asterisk is statistically not significant. mock-treated control (Fig. 3A) , while TGF-b3 expression did not alter (data not shown). Western blot analysis further suggested an increase in TGF-b1 and TGF-b2 expression in HCV-infected hepatocytes (Fig. 3B,C) . Similar analyses using xenograft tumor lysates were performed for TGF-b1 and TGF-b2 mRNA by quantitative real-time PCR (Fig. 3D) and protein analysis by western blot (Fig. 3E) . The results showed higher levels of TGF-b1 or TGF-b2 in tumor lysates.
We further examined for TGF-b mRNA expression in chronically HCV-infected human liver biopsy specimens by quantitative real-time PCR analysis. Liver biopsy specimens from chronic patients exhibited a significantly higher level of TGF-b1 gene expression compared to TGF-b2 (Fig. 4) . Two human control liver RNAs (C1 and C2) were pooled and used for comparison. The results from these experiments suggested that TGF-b1 is primarily up-regulated in HCV-infected hepatocytes in an in vitro culture and in infected human liver tissues. We had limited liver biopsy specimens and not enough to stratify with fibrosis stage of the patient sample used, and we did not use HCC liver specimens in this experiment.
TGF-b UP-REGULATES HSC ACTIVATION MARKERS AND MMP2
We examined if HCV replicon harboring cells upregulate fibrosis marker genes in fibroblasts. For this, we cocultured HFFs with Huh7.5 cells harboring fullgenome length HCV replicon from genotype 2a (Rep2a) for 24 hours. RNA isolated from cocultured cells was analyzed for fibrosis activation markers. RNA from HFFs was used as control. The results suggested an increased mRNA expression level of a-SMA, COL1A1, and CTGF by quantitative real-time PCR (Fig. 5A) .
We used CM from HCV-infected hepatoctes to investigate if soluble mediator stimulates fibroblasts. CM from HCV-infected hepatocytes was incubated with a human HSC line (LX2), and fibrosis markers were examined from RNA of these cells. Our results demonstrated up-regulation of a-SMA (>3-fold), COL1A1 (>4-fold), and MMP2 (>3-fold) compared to CM from mock-infected hepatocytes as control (Fig. 5B) . The activity of TGF-b in HCV CM was further examined separately using a functional reporter assay. HEK293 cells were transfected with a reporter construct, p3TP-luc, containing three TGF-b response elements with minimal promoter and incubated for 24 hours. Cells were incubated with CM from HCV-infected hepatocytes or CM incubated with anti-TGF-b1 or anti-TGF-b2 neutralizing antibody. Cells were lysed for 48 hours after transfection and the luciferase assay was performed as described. (21) We observed up-regulation of luciferase activity from HCV CM incubation (Fig. 5C ), suggesting the presence of TGF-b in CM. HCV CM-mediated upregulation was inhibited in the presence of TGF-b1 or TGF-b2 neutralizing antibody, further suggesting a role for the presence of TGF-b1 or TGF-b2 in activation of fibroblast markers. Reduced luciferase activity from the basal level likely indicates neutralization of endogenous TGF-b in HEK293 cells.
To investigate the role of TGF-b1 and TGF-b2 in HSC activation, we used commercially available TGFb1 or TGF-b2 and incubated with LX2 cells. TGFb3 was not included in our experiment as it is already known to have a negative effect on TGF-b1 expression and fibrosis inhibition. (22, 23) We analyzed for changes in the expression level of known HSC activation markers (a-SMA/COL1A1) and MMP2 genes compared to mock-treated negative control. Three different doses of TGF-b1 or TGF-b2 stimulation enhanced the mRNA expression of a-SMA, RNA from LX2 cells incubated with CM from mock-infected hepatocytes was used as control. HCV-mediated enhancement in TGF-b signaling was analyzed separately in HEK293 cells transfected with a TGF-b luciferase reporter (p3TP-luc) construct, containing a responsive element with a minimal promoter. Cells exposed to CM from HCV-infected hepatocytes or neutralized with anti-TGF-b1 or anti-TGF-b2 antibody (C). Luciferase activity was determined 48 hours posttransfection. Up-regulation of activation markers in immortalized HSCs (LX2) at the mRNA level by TGF-b was analyzed by quantitative real-time PCR. Activation markers (a-SMA/COL1A1) and MMP2 in LX-2 cells were induced at the mRNA level upon treatment with commercially available TGF-b1 (D) or TGF-b2 (E) at three different doses and analyzed by quantitative real-time PCR. Values are from three independent experiments 6 standard deviation. Statistical significance was analyzed using the two-tailed Student t test: *P < 0.05, **P < 0.01. COL1A1, and MMP2 (Fig. 4D,E) . MMPs play central roles in the development of hepatic fibrosis, (24) and increasing MMP2 status reflects potential for progressing liver fibrotic and cirrhotic changes in HCV patients. (25) 
ACTIVATION OF PRIMARY FIBROBLASTS AND INHIBITION BY TGF-b1-SPECIFIC ANTIBODY
Because TGF-b is increased upon HCV infection of hepatocytes, we determined whether CM from HCV-infected hepatocytes activates primary human HSCs in promoting fibrosis markers, and if anti-TGF-b1 or anti-TGF-b2 neutralizing antibody could inhibit up-regulation of fibrosis markers (a-SMA/ Col1A1/CTGF). Our results showed that CM from HCV-infected hepatocytes activates fibrosis marker genes in primary HSCs, which are reduced in the presence of TGF-b1 neutralizing antibody (Fig. 6A-C) . On the other hand, TGF-b2 antibody did not display significant inhibitory activity on these activation markers. These results further suggested a specific role of TGF-b1 in the activation of HSCs.
Discussion
Fibrosis and cirrhosis occur in most chronically HCV-infected patients, although the mechanism for this disease progression is not clearly understood. A number of mechanisms are reported to activate HSCs during HCV infection. (9, 13, 26) We have recently shown that chemokine (C-C motif) ligand 5 is induced in macrophages during exposure to HCV and that microRNA-19a carried through the exosomes from HCV-infected hepatocytes activates HSCs. (27, 28) In this study, we demonstrated that HCV-infected hepatocytes recruit activated fibroblasts, in part, by secretion of TGF-b. We have previously shown that HCV infection of primary human hepatocytes induces EMT-related gene expression and promotes TISC generation. (7, 8) TISCs are highly tumorigenic in immunodeficient mice. (7) In this study, we demonstrated that mouse fibroblasts are recruited into xenograft stroma of implanted TISCs into NSG mice. We   FIG. 6 . Activation of primary fibroblasts by HCV and inhibition by antibody to TGF-b1. Activation of fibroblast activation markers is primarily inhibited by TGF-b1-specific antibody in primary human HSCs (A-C). Up-regulated activation markers for primary human HSCs (a-SMA/Col1A1/CTGF) with CM from HCV-infected immortalized human hepatocytes are neutralized in the presence of TGF-b-specific antibodies. Activation markers were analyzed by quantitative real-time PCR. Values are from three independent experiments 6 standard deviation. Statistical significance was analyzed using the two-tailed Student t test: *P < 0.05, **P < 0.01. further showed that HCV-infected transformed human heaptocytes secrete TGF-b, which induces a cellular environment that promotes fibroblast activation for stromal changes. TGF-b1 and TGF-b2 are activated and TGF-b3 gene expression is suppressed in HCV-infected hepatocytes. (8) We analyzed the functional role of TGF-b, and it appeared to influence as a paracrine response from injected human hepatocytes upon mouse fibroblasts for generation of TAFs in the xenograft mouse tumor model. Tumors from implanted TISC of NSG mice exhibited a significantly higher expression level of TAF-associated markers (a-SMA and FSP-1). In addition, we observed collagen staining by sirius red in TAFs, suggesting stromal fibroblast activation in the TISC-induced tumor microenvironment. We have also demonstrated that TGF-b1 activates primary HSCs and TAF markers and stimulates MMP2 expression in LX2 cells and HFFs.
TGF-b1 is activated in HCV-infected hepatocytes and may have a role in virus replication. (29) Others have shown that HCV regulates TGF-b1 production by generation of reactive oxygen species in a nuclear factor-jB-dependent or microRNA-192-dependent manner. (30) (31) (32) The amino acid sequences of the TGFb1, TGF-b2, and TGF-b3 isoforms are 70%-80% similar. (33) To make an active protein, a mature TGFb protein dimerizes. (34, 35) TGF-b3 has the opposite effect of TGF-b1 in wound healing (22) and is antifibrotic. (23) In HSCs, TGF-b1 induces mothers against decapentaplegic 2/3 (Smad2/3) phosphorylation, causing stimulation of fibrosis marker. (36) (37) (38) TGF-b2 also induces Smad2/3 phosphorylation and causes stimulation of fibrosis markers in eye, bone, and heart. (39) (40) (41) On the other hand, TGF-b3 blocks Smad4 through up-regulation of Smad7 phosphorylation, (42) (43) (44) which is an inhibitor of TGF-b superfamily signaling. (45) There are reports on the differences between TGF-b1 and TGF-b2 in the liver: TGF-b1 induces Smad1 phosphorylation, but TGF-b2 has less affinity for Smad1 phosphorylation. (46) We know from our previous results that EMT is induced in HCV-infected hepatocytes and generates TGF-b. (8) CM from HCVinfected hepatocytes promotes human HSC activation for fibrosis markers. CM from HCV-infected hepatocytes contains TGF-b, and inhibition by antibody impairs the generation of fibrosis activation markers.
We observed that TGF-b stimulates TAF activation markers and MMP2 expression in LX2 cells and primary HFFs. CM from HCV-infected hepatocytes up-regulated fibrosis-related markers to a higher magnitude in primary human HSCs compared to immortalized LX2 cells. Human liver biopsy samples from chronically HCV-infected patients exhibited upregulation of TGF-b1 level, and TGF-b2 was high only in one out of the 10 samples examined in our study. TGF-b1 and TGF-b2 expression was reported to be higher at the cirrhosis stage than in normal liver, (46) but fibrosis stage did not co-relate with TGFb expression or viral load in our biopsy samples. HCV genotype 3a up-regulated TGF-b1 only in one sample used in our study. These results suggest that HCVinfected hepatocytes induce liver fibrosis through activation of HSCs in a paracrine manner and significantly influence the network of the tumor environment. However, we do not know whether this process in general serves to support outgrowth of non-TISC tumors. Interestingly, TGF-b is markedly up-regulated in pancreatic ductal adenocarcinoma. (47) Cancer cells and normal fibroblasts contribute to the emergence of TAFs through TGF-b and EMT. (48) On the other hand, the enhanced bone resorption in multiple myeloma bone lesions causes a marked increase in the release and activation of TGF-b. (49) Thus, TGF-b may support non-TISC tumor growth, and not be specific to HCC, by influencing the secretion of other growth factors and manipulation of the tumor microenvironment.
In summary, we demonstrated that HCV-induced TISCs promote cancer-associated fibroblast activation markers and that CM from HCV-induced TISCs indeed activates fibrosis markers through TGF-b and is reduced following neutralization by specific antibody. These results suggest that HCV-infected hepatocytes induce liver fibrosis through activation of HSCs by TGF-b and that a preneoplastic or tumor state of the hepatocytes influences the network for the TAF environment.
